Back to Journals » OncoTargets and Therapy » Volume 12

Brain metastases from breast cancer may respond to endocrine therapy: report of two cases

Authors Wang Q, Sun B, Liu C, Shi S, Ding L, Liu J, Wu S

Received 19 September 2018

Accepted for publication 31 December 2018

Published 19 February 2019 Volume 2019:12 Pages 1389—1393

DOI https://doi.org/10.2147/OTT.S188143

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Dr Sanjeev Srivastava


Qian Wang,* Bing Sun,* Chao Liu, Sanzhong Shi, Lijuan Ding, Jiannan Liu, Shikai Wu

Department of Radiation Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China

*These authors contributed equally to this work

Abstract: Brain metastases from breast cancer have a poor prognosis. There have been few cases reported where patients with breast cancer and brain metastases respond well to endocrine therapy (tamoxifen or letrozole). Here, we report the cases of two breast cancer patients with brain metastases who responded to medroxyprogesterone acetate and fulvestrant, respectively. These cases indicate that endocrine therapy could be very effective in the management of brain metastases from breast carcinoma.

Keywords: breast cancer, brain metastases, endocrine therapy, medroxyprogesterone acetate, fulvestrant

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]